Teva Advances Pipeline of Movement Disorder Assets with Announcement of Positive Top-Line Data from the First Pivotal Study of Investigational Treatment for Patients with Tardive Dyskinesia
June 16, 2015 at 08:02 AM EDT
Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced positive top-line results from the pivotal clinical study Aim ...